Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects

Cancer Gene Therapy

Volumn 14, Issue 3, 2007, Pages 316-326

  Wenger, T ^a,b   Mattern, J ^a,c   Haas, T L ^d   Sprick, M R ^d   Walczak, H ^d   Debatin, K M ^e   Buchler M W ^f   Herr, I ^a,f  

^a Research Group Molecular OncoSurgery   (Germany)

^b CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^c Clin Coop Unit Nuclear Medicine   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Gene therapy for solid tumors; Retroviral vectors; Translational research

Indexed keywords

LENTIVIRUS VECTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; EMBRYO; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELLS, CULTURED; FEMALE; GENE THERAPY; HUMANS; KIDNEY; LIGANDS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; VIRION;

MUS MUSCULUS;

EID: 33847035197     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701016     Document Type: Article

References (40)

1. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 2003; 18: 1-6.
2. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
3. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 2002; 21: 4520-4530.
4. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337-348.
5. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-483.
6. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
7. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000; 97: 1754-1759.
8. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
9. Mori E, Thomas M, Motoki K, Nakazawa K, Tahara T, Tomizuka K et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 2004; 11: 203-207.
10. Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 2003; 3: 615-622.
11. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508-2518.
12. Rainov NG, Ren H. Gene therapy for human malignant brain tumors. Cancer J 2003; 9: 180-188.
13. Hughes RM. Strategies for cancer gene therapy. J Surg Oncol 2004; 85: 28-35.
14. McNeish IA, Bell SJ, Lemoine NR. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Therapy 2004; 11: 497-503.
15. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001; 4: 257-266.
16. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61: 3330-3338.
17. Mohr A, Henderson G, Dudus L, Herr I, Debatin K-M, Weiher H et al. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Therapy 2004; 11: 534-543.
18. Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S et al. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 2004; 10: 3535-3541.
19. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002; 21: 8020-8028.
20. Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002; 62: 7170-7174.
21. Ucur E, Mattern J, Wenger T, Okouoyo S, Schroth A, Debatin KM et al. Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells. Br J Cancer 2003; 89: 2155-2162.
22. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Therapy 2000; 7: 20-23.
23. Wiznerowicz M, Trono D. Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol 2005; 23: 42-47.
24. Wenger T, Mattern J, Penzel R, Gassler N, Haas TL, Sprick MR et al. Resistance by intracellular retention of TRAIL receptors by lentiviral TRAIL transfer. Cell Death and Diff 2006; 13: 1740-1751.
25. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH et al. Glucocorticoid co-treatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003; 63: 3112-3120.
26. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987; 7: 379-387.
27. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N et al. TRAIL-R2: a novel apoptosismediating receptor for TRAIL. EMBO J 1997; 16: 5386-5397.
28. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
29. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
30. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
31. Herr I, Wilhelm D, Boehler T, Angel P, Debatin K-M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 1997; 16: 6200-6208.
32. Ghosh SK, Wood C, Boise LH, Mian AM, Deyev VV, Feuer G et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidinemediated inhibition of NF-kappa B. Blood 2003; 101: 2321-2327.
33. Rohn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 2001; 20: 4128-4137.
34. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28: 973-982.
35. Monleon I, Martinez-Lorenzo MJ, Monteagudo L, Lasierra P, Taules M, Iturralde M et al. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol 2001; 167: 6736-6744.
36. Van Maele B, De Rijck J, De Clercq E, Debyser Z. Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J Virol 2003; 77: 4685-4694.
37. Strehlow D, Jodo S, Ju ST. Retroviral membrane display of apoptotic effector molecules. Proc Natl Acad Sci USA 2000; 97: 4209-4214.
38. Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 2005; 106: 3474-3482.
39. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activationinduced cell death. Nature 2005; 434: 88-93.
40. Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer PH, Debatin K-M et al. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer 2004; 108: 580-587.